Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1900 participants
INTERVENTIONAL
2025-11-06
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT05838417
Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women
NCT06441474
Mammogram Mail- and Phone-based Interventions
NCT05853848
Communicating Objective Risk for Personalized Decision Making About Mammography
NCT01686360
Testing Conversation Aid in Practice
NCT06011434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control condition
Participants receive basic information about what mammography screening is
No intervention
This is the control condition in which only basic information about mammography screening.
Harm/benefit language, survivability information
Outcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is included
Harm/benefit language vs. outcomes that can happen
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Breast cancer survivability information
Information about improvements over time in the survivability of breast cancer is provided vs. not
Harm/benefit language, no survivability information
Outcomes of screening are referred to as "harms" and "benefits"; information about breast cancer survivability is not included
Harm/benefit language vs. outcomes that can happen
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Outcomes that can happen language, survivability information
Outcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is included
Harm/benefit language vs. outcomes that can happen
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Breast cancer survivability information
Information about improvements over time in the survivability of breast cancer is provided vs. not
Outcomes that can happen language, no survivability information
Outcomes of screening are referred to as "outcomes that can happen"; information about breast cancer survivability is not included
Harm/benefit language vs. outcomes that can happen
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Harm/benefit language vs. outcomes that can happen
Information about mortality benefit, false positives and overdiagnosis are referred to throughout the communication as either "harms" and "benefits" or "outcomes that can happen".
Breast cancer survivability information
Information about improvements over time in the survivability of breast cancer is provided vs. not
No intervention
This is the control condition in which only basic information about mammography screening.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
39 Years
49 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Anschutz
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-0635
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.